We have located links that may give you full text access.
Stereotactic radiation therapy for oligometastatic esophagogastric adenocarcinoma: outcome and prognostic factors.
British Journal of Radiology 2023 Februrary 21
OBJECTIVES: The aim of this study was to evaluate clinical results and prognostic factors in a cohort of patient with oligometastatic esophagogastric adenocarcinoma treated with Stereotactic Radiation Therapy (SRT).
METHODS: This retrospective study included patients affected by 1 to 3 metastases treated with SRT from 2013 to 2021. Local control (LC), overall survival (OS), progression free survival (PFS), time to polymetastatic dissemination (TTPD) and time to systemic therapy change/initiation (TTS) were evaluated.
RESULTS: Between 2013 and 2021, 55 patients were treated with SRT on 80 oligometastatic sites. Median follow-up was 20 months. Nine patients had local progression. 1 and 3 years LC was respectively 92 and 78%. 41 patients experienced further distant disease progression, median PFS was 9.6 months, 1 and 3 years PFS was respectively 40 and 15%. 34 patients died, median OS was 26.6 months, 1 and 3 years OS was respectively 78 and 40%. During follow up, 24 patients changed or initiated a new systemic therapy; median TTS time was 9 months. Twenty-seven patients experienced poliprogression, 44% after 1 year and 52% after 3 years. Median TTPD was 8 months. The best local response (LR), tyming of metastases and PS were related with prolonged PFS on multivariate analysis. LR was correlated with OS at multivariate analysis.
CONCLUSIONS: SRT represents a valid treatment for oligometastatic esophagogastric adenocarcinoma. CR correlated with PFS and OS, while metachronous metastasis and a good PS correlated with a better PFS.
ADVANCES IN KNOWLEDGE: In selected gastroesopagheal oligometastatic patients, SRT can prolong OSLocal response to SRT, metachronous timing of metastases and better PS improve PFSLocal response correlates with OS.
METHODS: This retrospective study included patients affected by 1 to 3 metastases treated with SRT from 2013 to 2021. Local control (LC), overall survival (OS), progression free survival (PFS), time to polymetastatic dissemination (TTPD) and time to systemic therapy change/initiation (TTS) were evaluated.
RESULTS: Between 2013 and 2021, 55 patients were treated with SRT on 80 oligometastatic sites. Median follow-up was 20 months. Nine patients had local progression. 1 and 3 years LC was respectively 92 and 78%. 41 patients experienced further distant disease progression, median PFS was 9.6 months, 1 and 3 years PFS was respectively 40 and 15%. 34 patients died, median OS was 26.6 months, 1 and 3 years OS was respectively 78 and 40%. During follow up, 24 patients changed or initiated a new systemic therapy; median TTS time was 9 months. Twenty-seven patients experienced poliprogression, 44% after 1 year and 52% after 3 years. Median TTPD was 8 months. The best local response (LR), tyming of metastases and PS were related with prolonged PFS on multivariate analysis. LR was correlated with OS at multivariate analysis.
CONCLUSIONS: SRT represents a valid treatment for oligometastatic esophagogastric adenocarcinoma. CR correlated with PFS and OS, while metachronous metastasis and a good PS correlated with a better PFS.
ADVANCES IN KNOWLEDGE: In selected gastroesopagheal oligometastatic patients, SRT can prolong OSLocal response to SRT, metachronous timing of metastases and better PS improve PFSLocal response correlates with OS.
Full text links
Related Resources
Trending Papers
Insomnia in older adults: A review of treatment options.Cleveland Clinic Journal of Medicine 2025 January 2
How We Treat ANCA-Associated Vasculitis: A Focus on the Maintenance Therapy.Journal of Clinical Medicine 2025 January 2
Allergic rhinitis.Allergy, Asthma, and Clinical Immunology 2024 December 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2025 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app